Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NBP for Prevention of Nab-paclitaxel Induced Neuropathy in Metastatic Breast Cancer
NCT04675450Phase 2Withdrawn
- Sponsor
- Conjupro Biotherapeutics, Inc.
- Start
- Jun 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in chemotherapy-induced peripheral neuropathy (CIPN) comparing NBP Arm with Placebo Arm (2 arms). Primary endpoint: Mean Change from Baseline in EORTC Quality of Life Questionnaire Chemotherapy-Induced Peripheral Neuropathy (EORTC QLQ-CIPN20) Sensory Subscale at Week 15. Planned start Jun 2023; status: withdrawn.
02
Drugs
butylphthalide
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on NCT04675450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04675450.